Takeda’s CMV Drug Maribavir Earns FDA AdCom Backing

Takeda Pharmaceutical said on October 8 that the US FDA’s advisory committee has given its thumbs-up to maribavir for the treatment of post-transplant recipients with cytomegalovirus (CMV) infection and disease refractory to treatment with or without resistance. The FDA’s Antimicrobial...read more